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PREFACE
This paper results from and further elaborates on an expert workshop 
organised by the EPFL International Risk Governance Center on 24 September 
2016: ‘Governance of impacts of precision medicine’.1 The objective was to 
discuss how to move forward an interdisciplinary and multi-stakeholder 
agenda for the development of precision medicine (PM). The workshop offered 
a platform for conversation on matters of risk governance, discussed issues 
of policy, adaptive regulation, insurance and creating confidence between 
society, patients, industry and regulators. 
Specific questions discussed included:
• What is the vision for precision medicine?
• What are the expected impacts and challenges? 
• How to drive the innovation process?
• How can insurance systems adapt?
• How to avoid, prevent or mitigate the possible various negative 
consequences?
• How to adapt regulation?
Precision medicine is expected to deliver numerous 
benefits to individuals, by significantly improving the state 
of health of each, and thus of the population. It is based 
on a better scientific understanding of the components of 
health and diseases. However, its development presents 
some critical challenges, which require a clear strategy 
and a comprehensive roadmap to support a smooth 
transition. The purpose of the overarching roadmap 
proposed by IRGC in this brief is to recommend a 
structured process that organisations can follow in their transition 
towards the development of precision medicine. The process is adaptable, 
and each organisation should further develop it to align with its own needs, 
culture and objectives.
This paper does not intend to prescribe certain policy and regulatory 
choices concerning such important issues as privacy, confidentiality, equal 
right of access, or the basis of evidence generation (uncertainty management 
Precision medicine (PM) is 
an emerging field for disease 
diagnostic, prevention and 
treatment that considers 
individual variability in genes, 
environment and lifestyle.
It aims to improve the health 
status of patients, and to help 
and support the prevention of the 
onset of a disease.
1 The workshop was attended by experts from Switzerland, the EU and the US, 
representing science and research, medical practice, policy, regulation and industry.
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in safety and efficacy assessment) for new precision medicine diagnostics, 
prevention strategies and therapies. What each country or organisation will 
decide is context-specific and depends on its own culture and level of interest 
or involvement in precision medicine. We anticipate 
that differences between cultures, legal frameworks, 
societal contexts, economic conditions, health priorities 
amongst other aspects will lead to a diversity of modes 
of development of precision medicine in the world.
The recommendations are primarily for an audience in 
governmental organisations or other public institutions, 
which may use the roadmap as a set of generic guidelines 
for developing their own strategy for precision medicine 2. 
It suggests the need for national or international initiatives 
for precision medicine. Other actors in the public and 
private sectors, such as patients associations, healthcare 
payers, civil society representatives, professional and 
scientific associations might also be interested in a roadmap process when 
they develop their own strategies.
In scientific and technological 
areas marked by  rapid 
development, high expectations 
and uncertainties about existing 
and future challenges, it is 
rarely possible to say which 
regulatory, economic or even 
scientific options are the best. 
It is advisable to agree on a 
process to work collaboratively 
towards progressively reducing 
the uncertainties and identifying 
the preferred options.
2 See Appendix 1: About roadmaps for precision medicine.
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Any new technology or scientific development that 
promises to deliver major benefits and revolutionises 
existing practices will challenge institutions, decision 
makers and practitioners.3 Precision medicine (PM) is an emerging field 
for disease  diagnostic, prevention and treatment that considers individual 
variability in genes, environment and lifestyles.
Answering the question of which benefits precision medicine can bring to the 
wider society and how desirable change can be organised, begins with the 
creation of a space for dialogue between stakeholders, including the scientific 
community, the health sector, industry, patients, citizens 
and other actors. Ultimately, the deployment of precision 
medicine will result from:
• A multi-dimensional convergence of views – innovation 
in science and medical research, top-down policy 
decisions, industry, patients, citizens who register and 
share their health and lifestyle data, etc. 
• A shared and broad societal understanding of the risks 
and benefits, which will create the basis for political will and fair policy 
choices.
A shared long-term vision for precision medicine can only emerge from 
dialogue. Then, steps to reach the vision will be established.
The deployment of precision medicine will stem from progress in biomedical 
science but IRGC considers that it will only succeed if it improves health 
outcome, for the benefit of individuals as well as the economy and society 
overall. We believe that an agreement on this objective has the advantage 
of highlighting those issues that matter for triggering buy-in from important 
stakeholders outside of the scientific community, emphasising that social 
and economic benefits can be gained, and embedding the vision into local 
conditions for its practical implementation. 
INTRODUCTION
DATA-DRIVEN PRECISION 
MEDICINE FOR ALL
3 See Appendix 3 for information about IRGC generic recommendations for the governance of emerging issues involving inter-related 
risks and benefits
Unlocking the promises of 
biomedical data science for public 
health
Combining rigorous analytics, 
large-scale biological datasets 
and clinical outcomes to uncover 
the mechanisms of disease, cure 
diseases and improve health and 
wellbeing.
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Precision medicine is:
• Data-driven. Data-driven science is entering a new era, not only because of 
the sheer volume and the incredible variety of data - the usual characteristic 
of Big Data - but also because the most available data were not purposely 
collected for aims they end up serving. Data-driven science raises several 
scientific, ethical and legal questions. Given the breadth of information 
that is needed for precision medicine, issues arise about how data must 
be collected, what are the new instruments needed to support distributed 
and incremental data analytics, and how data from medical, personal 
and non-medical public or administrative sources can be handled, 
without jeopardising patient protection. In addition, the interpretation of 
heterogeneous data raises immense challenges in semantics.
• Personalised. Precision medicine aims to meet the demand of individuals 
to benefit the best-adapted prevention and treatment strategies. Issues 
include how to deliver a service that is patient-centred and prioritises a 
trust relationship with the patient.
• Global. Precision medicine must benefit society, not just a few individuals. 
Precision medicine is often described as predictive, personalised, preventive, 
and participatory (P4) (Hood & Friend, 2011). The term ‘mass customisation’ 
can also be used to describe that precision medicine is expected to deliver 
health and medical care that is both personal (‘customised’) and global 
(‘mass’), towards ‘precision health’. 
The field is complex. Precision medicine develops from increased knowledge 
about individual variety in genes, but also complex risk and protection factors 
influencing health and diseases such as lifestyles, life histories or environment, 
over a long time span, and innovation in biostatistics and biomedical 
informatics. Relationships between biomarkers and disease outcomes are 
very complex and still obscured by much uncertainty. Our growing scientific 
and biomedical understanding of the complexity of how health and disease 
develop and can be explained is a cause for optimism as much as it is a 
call for caution.
In order to address the main challenges to the implementation of precision 
medicine, a structured and comprehensive approach is recommended that 
is incremental and objective-driven.
Five specific challenges that implementing a roadmap for precision medicine could help address
Challenge 1 Trust: engaging citizens and patients in biomedical data collection and sharing schemes
Challenge 2 Data security: securing data transactions for privacy and confidentiality (including cyber 
security), while at the same time making the data available for research (interoperability)
Challenge 3 Incentives: helping scientists and technologists organise so that they work more effectively 
together (competition, rewards and incentives)
Challenge 4 Economics: making the case that investing in precision medicine (research and 
implementation) is cost-effective
Challenge 5 Regulation: helping regulators design licensing mechanisms to assess efficacy and safety  
with acceptable certainty without constraining innovation
Table 1: Challenges that  
implementing a roadmap for precision 
medicine could help address
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Figure 1: A roadmap for precision medicine
Figure 1 below summarises the recommended roadmap (process)
IRGC’s proposed 
roadmap for the 
development of 
precision medicine
Dialogue between:
• Health sector
• Industry and non-medical domains
• Citizens and patients
• Regulators and payers
• Academia
• Policymakers
• Data collection, sharing and analytics
• Precision diagnostics and treatment
• Personalised prevention
• Complex traits and new biomedical 
data-based therapies
• Type and quality
• Privacy and condentiality
• Issues of consent
• Data sharing
• Interoperability
• Biobanks
• IP issues
• Planned adaptive licensing
• Performance-outcome based 
reimbursement
• Pay for diagnostic and data
• Post-market surveillance
2. Incremental
implementation
1. Creating appropriate 
context conditions
3. Addressing 
the data issue
4. Reforming regulation 
and payment systems
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1.
CREATING FAVOURABLE 
CONTEXT CONDITIONS
A joint long-term vision of precision medicine can emerge from a fruitful 
dialogue among stakeholders. Who will eventually profit from the exploitation 
of biomedical data?
Each institution (such as a public health administration or a medical 
insurance) that commits to developing precision medicine should first work 
to create favourable context conditions for that purpose. Favourable context 
conditions can be created when there is a space for dialogue with all important 
stakeholders, from research to clinical use and society, about how to translate 
the science of genomics and other data-driven biomedical sciences into 
clinical applications. Otherwise, PM will be regarded as something to solve 
biomedical problems, rather than to help patients. If PM is only available for 
a few individuals, societal buy-in may be insufficient to trigger the necessary 
fundamental changes that regulators and payers will have to make. 
In Europe and for some international organisations such as the World 
Health Organization (WHO), there is a general agreement that principles for 
a successful implementation will at least include: Non-discrimination (personal 
data cannot be used against individuals) and social justice (affordable access, 
through universal health care or other). (World Health Organization, 2004)
The success of PM depends on trust. The quality of the data on which PM 
can build - and their relevance for the whole population - will depend crucially 
on how many citizens agree to have their medical, genomic and phenotypic 
data collected in databases, and shared according to trustworthy sharing 
schemes. Similarly, trust in how risk assessment about quality, efficacy 
and safety is performed is key. However, precise definitions, metrics and 
regulations for implementing these key principles are lacking and must result 
from a wide engagement with stakeholders and society.
This requires for policymakers to engage with scientists, the health sector 
(medical and clinical field), patients and citizens, regulators, payers, and 
industry. The aim is to establish political will and societal buy-in, based on 
trustworthy partnerships. 
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Engaging with the health sector
The field of medicine is changing. Health care professionals must adapt, 
together with others in the healthcare universe, particularly by helping 
individuals to become active partners in their own health. (Topol, 2012)
Training physicians for PM
First, the curriculum of medical studies will need to put emphasis on Big 
Data-related competences including biostatistics, bioinformatics and 
genomics. Physicians will soon be provided with large-scale genetic testing 
results for many diseases. This will pose new challenges: how to explain 
risk, especially probabilistic, and how to handle numerous new risk factors. 
As a consequence, medical training will focus on prevention of disease, 
on understanding uncertainty around links between cause (DNA, genomic 
analysis, phenotypic data) and effects, on deciding under uncertainty, and 
on communication. It is difficult to communicate uncertainty. As biomedical 
science sees a ‘reproducibility crisis’ (Nature, 2016), the prediction tools 
of data-centered medicine will need to allow faster translational medicine, 
as well as new rules to handle the evidence required, and the risks and 
responsibilities associated.
New healthcare specialists
Precision medicine will require new specialists such as ‘Big Data wranglers’, 
to reflect the new process of collecting, analysing, administrating and working 
with large amounts of data. PM will also require ‘health coaches’ or health care 
‘navigators’ who can help patients navigate and understand their health and 
disease, accompanying them through their journey into precision medicine. 
The medical field is poised to become even more multi-disciplinary than it 
already is.
Engaging with industry and new actors 
from the non-medical domain
Business is one of the key drivers of PM. The pharmaceutical industry will 
undergo dramatic changes, and will have to develop new business models 
that make it rewarding to participate in PM, all the while keeping business 
interests and those of patients and society as aligned as possible. New 
actors from outside the medical domains, such as tech firms, Big Data or 
telecommunication companies, tend to innovate fast and effectively. They may 
challenge existing conventions or values in the medical sector. It is critical 
that initiatives for PM involve industry and new actors in the field.
Already today, some patients with unmet medical needs decide to bypass 
established safety and efficacy standards of their own country, and get 
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medical treatments in countries that accept experimentation on patients 
before the full extent of testing for safety and efficacy is completed, despite 
high levels of uncertainty about outcome.
Looking to the future, it may be that society and new private actors form 
unexpected partnerships, following the social media model for example, 
and overdrive current institutional settings including existing public health 
systems. An even larger and deeper transformation of medicine could thus 
be triggered by precision medicine. If individuals would gain full control of 
their own health and medical data, which could be the case in the future 
if new rules about data generation, ownership, use and control would be 
progressively developed, then individuals would become empowered to make 
private agreements with convincing new industry actors. Such a scenario 
justifies considering seriously issues such as autonomy, consent and groups 
of interest. 
In the debate about the ownership and protection of data and access to 
resulting information, intellectual property (IP) issues come into play. How 
these issues are dealt with in the context of genetic data and information will 
determine to a large extent how innovation is encouraged and how industry 
is incentivised to invest in precision medicine. This debate will also have 
an impact on possible new responsibility or liability regimes in the case of 
unattended negative consequences.
Engaging with citizens and patients
Precision medicine will trigger many potentially fundamental changes in how 
the relationship with patients is organised and how health and disease are 
viewed. It is necessary to engage with society as a whole, not just patients. 
Engaging with citizens 
Public institutions must engage with citizens, to create the space for dialogue 
about how society and the economy will adopt precision medicine. Citizens 
will become active participants in the development of PM, first as data and 
consent providers. In particular, critical choices such as those on ethics and 
values, discrimination or solidarity must result from an alignment between 
societal preferences and public policy. To make informed decisions, citizens 
must be involved in a two-way dialogue about the benefits that they expect 
from precision medicine as well as the related challenges, both for them and 
for society, in particular regarding:
• Ethical implications. Discussions about ethics may come in conflict 
with policy and political reality. Any ethical framework would have to be 
discussed with citizens, in order to create the legitimate space (boundaries) 
for PM to develop, including the limits that PM must not cross (e.g. 
discrimination, or the border between prevention and eugenism).
• Data collection and sharing. Important choices have to be made as to 
how biomedical data and their scientific implications translate into medical 
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practice. Genomic and other ‘-omic’ data need to be linked to other health, 
lifestyle and environment data (‘Big Data’). This involves issues of consent, 
data collection, access, use and sharing, as well as ethical and economic 
considerations on privacy, security and trust. (See section 3: Addressing the 
data issue). The importance of consent to use health data must be noted. 
Engaging with patients 
The need to put the patient at the centre of the attention and the medical 
practice is a recurring theme in PM. However, studies show that patients who 
don’t have immediate and unanswered medical needs are not convinced 
yet by the potential benefits for them. Engaging patients in PM will require a 
new type of communication between physicians and patients, to subtantiate 
and explain that there is a continuum between health and disease, to trigger 
behavioural change, and to co-develop a new taxonomy of diseases. Two 
aspects are particularly worth mentioning in the context of a roadmap:
• Genomics and health literacy. It is often difficult for patients to understand 
the implications of DNA testing, genomic analysis, and probabilistic 
predisposition. 
• Patient empowerment and responsibility. Because patients may be put 
more in control of their own health (in particular when a predisposition to a 
certain condition is detected and the patient is informed of this), a greater 
responsibility may be assigned to them. Patients will be empowered to 
make their own, well-informed decisions. They may also be incentivised, 
possibly through adaptive medical insurance schemes, and through 
their participation in patient monitoring programmes using sensor-based 
medical devices for ‘mobile health’. 
There is also the potential for patients and citizens to become involved as 
citizen scientists. They may be given the opportunity to start their own clinical 
studies (under the guidance of academic scientists). The best way to improve 
health literacy is to the engage with one’s own health and health data.
Communication with citizens and patients must be transparent (including 
about topics that are not well understood). Citizens must be enabled to 
evaluate if PM is developed for their own good and can improve population 
health, with a fair distribution of benefits and risks. PM and health are only 
possible with the active engagement of citizens and patients, who will provide 
key information to understand the phenotypic variability of diseases.
Engaging with regulators and payers (insurers)
Precision medicine challenges existing licensing and regulatory frameworks, 
and is likely to be expensive, at least before it can exert an impact on 
healthcare and related expenses (such as rehabilitation and absence from 
work) by optimising individualised prevention and therapies. Today, in many 
countries, regulators and payers are not prepared for the ‘precision medicine 
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revolution’. It is difficult for them to engage with those who develop PM 
and many of them may not even be aware of its implications. Information, 
communication and evidence-based dialogue must be a priority. 
Decisions by those who want to develop PM should result from engaging with:
• Rule makers (legislators and regulators), who design, decide, implement 
and enforce the rules. This includes licensing authorities such as the 
European Medicines Agency (EMA) or the US Food and Drug Administration 
(FDA) that authorise diagnostic tools and therapies based on safety and 
efficacy. This also concerns any legal rights for patients, for example to 
obtain copies of all their health relevant data and to decide about their 
use for research.4
• Payers, who pay or reimburse diagnostics, prevention and therapies, 
based on comparative cost-benefit or cost-efficiency analyses. Payers are 
enablers or constrainers of PM. Some payers are insurance companies, 
which have strong expertise in risk assessment, balancing risk and benefit. 
Their knowledge is useful to the new field of PM, where cost-effectiveness 
assessment might differ from those in conventional medicine. Conventional 
healthcare reimbursement is based on standardised treatments for large 
groups of population. Precision medicine, however, targets effective 
treatments to smaller groups.
One particular aspect that payers have to discuss is to which extent they 
apply the principles of non-discrimination and fair access. One potential 
point of contention, for instance, is to decide whether insurance premiums 
can be contingent on lifestyle or behaviour, especially in the case of 
probabilistic predisposition. Insurance operates within the boundaries 
set by regulation. Some legislations may prioritise aspects such as ethics 
or affordability. 
• Insurers in general, who may also be faced with changing conditions 
regarding the liability of medical practitioners related to the use of PM.
In conclusion, engagement with important groups of stakeholders will be 
the cornerstone for establishing a vision for PM and for creating legitimate 
policies, legal frameworks and viable business conditions. The expected 
benefits for each group of stakeholders to engage with others are many folds. 
It includes the elaboration of guidelines for collaboration.
4 See article 20 (Official Journal of the European Union, 2016).
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2.
STEP-WISE 
IMPLEMENTATION OF 
PRECISION MEDICINE
The field of precision medicine is still in its infancy and likely to see several 
more cycles of development. Implementation will be a complex process. 
As such, institutional action can target four separate ‘horizons’ in the 
development process: 
• Horizon 1. The first horizon is the organisation and shareability of large-
scale collection of biomedical and other data, for an interoperable 
framework of data streams. Genomic data are the most prominent. 
• Horizon 2. A second milestone consists of taking advantage of ‘low 
hanging fruits’, with applications of PM that demonstrate clinical quality 
and utility, and cost-effectiveness when a precise diagnostic can be made 
and when a cure is at disposal. The advent of pharmacogenetics has 
already enabled better use of existing drugs. 
• Horizon 3. The third step, involves moving to applications where, based 
on ‘Big Data’, we see a possible (but not certain) predisposition for a 
disease, and where targeted prevention can maintain and develop health 
and wellness. 
• Horizon 4. The final step includes applications to complex traits (e.g. 
biology of ageing, higher brain functions) where there are uncertainties 
about causes of diseases affecting these traits, no recognised biomedical 
therapies and no clear data-based approaches, with many questions on 
safety, efficacy, cost-effectiveness and longer-term consequences. 
The roadmap begins with applications of PM that are potentially inexpensive 
and with a low level of uncertainty, and moves progressively to applications 
that are likely expensive and with a high level of uncertainty. This proposed 
implementation of PM may be simplistic, give undue importance to 
deterministic aspects of biomedical data sciences, or even be seen as 
inaccurate by some scientists. However, the underlying rationale is to develop 
simple messages to communicate, to respond to the current public interest in 
genomics, to explain the importance of investing in the field to non-experts, 
and to focus on cost and return on investment. 
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In addition, a step-wise implementation of precision medicine will also focus 
on:
• The need to increase the value of health care systems, which implies the 
acceleration of the development of new biomedical diagnostics, tools, 
therapeutics and other innovations.
• The need to demonstrate benefits to human health, which will contribute 
to creating public acceptance. This implies moving as soon as possible 
from Horizon 1 to Horizons 2 and 3.
5 See Appendix 2: Characterising the knowledge about an issue to determine management strategies.
6 See for example initiatives of the Global Alliance for Genomics and Health, for “working together to create interoperable approaches 
to catalyze projects that will help unlock the great potential of genomic data”, www.genomicsandhealth.org.
7 e.g. sickle cell disease (SCD), beta-thalassemia, severe combined immune deficiency.
“Precision medicine is about 
diagnosing and treating patients 
in a way which is specific to 
them, thereby giving the greatest 
chances of success. This involves:
• Precise diagnosis – using data 
insights to more effectively 
group patients based on 
their predicted response to 
treatments.
• Precise treatment – delivering 
treatments for groups of 
patients that are reliable, 
repeatable and with the fewest 
side effects.
• P re c i s e  ou t comes  – 
understanding the impact of 
those treatments on patients 
and what affects those 
outcomes might have.”
Precision Medicine Catapult (UK)
pm.catapult.org.uk/about-us/
what-is-pm
Horizon 1: Data collection, sharing and analytics  
Creation of meaningful subpopulations
Many of the initial benefits will accrue from using genetic and other biomedical 
information to group individuals into meaningful subpopulations or cohorts 
that are valid for improved health decisions and outcomes. This requires the 
creation of large databases. In addition, the databases must be designed 
for optimising data flows, so that data can be shared with others. See also 
section 3, addressing the data issue.
Recommendation: Design and implement large-scale programmes for DNA 
testing, collection and sharing of medical and health records. The objective 
is that doctors, ‘data wranglers’, and scientists can search the genetic 
information and other records of millions of individuals to identify patterns 
and improve diagnostics and predictions from past clinical applications.6
Horizon 2: Precision diagnostics  
Enabling precision treatments 
In some cases, we understand the cause of a disease thanks to genomic and 
other biomedical data. A prognostic can be made, indicating how to treat the 
disease by appropriate therapeutic agents. In the future, this might involve 
correcting the defective allele. In this case, there is a direct connection between 
the individual data and therapies with proven effect, for example certain cancer 
or inherited conditions 7. The field of pharmacogenetics is among the first 
applications of PM, based upon the understanding of differential responses 
to treatments in different patient groups. Pharmacogenetics develops with 
the understanding and targeting of underlying genetic mutations of disease, 
The suggestion presented in this section follows generic recommendations 
developed and applied by IRGC to consider the knowledge collected about 
a risk issue in order to design appropriate management strategies.5 
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8 “A one-shot cure effected through gene therapy might cost hundreds of thousands of dollars per patient up-front. But over the long 
term (assuming there is no need for additional therapy and a significantly improved quality and length of life), these drugs will be 
eminently cost effective, if not cost reducing” in (Howard & Huber, 2016).
insofar as inherited genetic differences explain how individuals respond to 
drugs. Such strategies target some rare disorders that affect few individuals. 
Rare diseases in aggregate represent an enormous cost to the health care 
system but in many cases they are excellent pilots for PM approaches. (Orkin 
& Reilly, 2016) 8
General recommendation: Understanding, continuing to experiment and 
communicating the benefits of precision medicine in these areas will hopefully 
contribute to demonstrating that precision medicine can be more cost-
effective than conventional medicine. This is especially the case when also 
taking into account broader aspects of health and medical costs, such as 
overtreatments, untreated/uncontrolled side effects, or quality of life.
Specific recommendation: Communicate with society about economic 
facts to demonstrate that, in some cases, it is globally beneficial to spend 
money on a few individuals. This can contribute to increasing the value of 
health care systems, with decreasing costs over the medium- and long-term.
Horizon 3: Personalised prevention  
Personalised biomedical profiling leading to precision 
disease prevention and maintenance of wellbeing
Prevention is potentially the most cost-efficient way to treat disease. The 
economics of vaccines have demonstrated that, for a wide diversity of 
conditions, preventing disease is less expensive than treating it. Large-
scale DNA sequencing and genome analysis have the potential to detect 
predispositions to certain diseases that can to a certain extent be prevented 
by adapting behaviour. The patient consequently has the opportunity to adapt 
his or her lifestyle to reduce disease risk. The main obstacles to overcome are:
• Understanding uncertainty and probability. Genetic testing can help 
identify predisposition to a condition, but without timing and certainty of 
development of the condition. Today, only monogenetic dominant diseases 
can be predicted with genetic tests. 
• Triggering a change in lifestyle or consumption if the positive outcome is 
uncertain. Insights from behavioural economics and other social sciences 
have shown that it is very difficult to ‘nudge’ individuals into sustainable 
lifestyle changes, especially when the scientific proof of the health outcome 
based on behavioural change is scarce. Behavioural research for effective 
preventive strategy is needed.
• Creating the financial incentives that will be needed. Health care systems 
recommend prevention, but the cost of prevention is often at the patients’ 
expense. The financial incentive to engage in prevention is low.
• It is important that doctors do not make moral judgements about their 
patient, who would be held responsible for their condition. It is equally 
important to carefully evaluate the benefits expected from behaviour- or 
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compliance-linked health insurance premiums when the health outcome 
is uncertain.
Recommendation: Develop schemes to pay for genetic testing and 
counselling patients on behaviour change that would avoid the development 
of certain diseases. 
Horizon 4: Complex traits and new biomedical  
data-based therapies  
Personalised medicine and uncertainty about 
safety, efficacy and cost-effectiveness
In many cases, there is no direct connection (maybe just a suspicion of 
connection) between the cause of a disease and the biomedical (including 
genetic) information. This includes complex traits where the scientific 
understanding is still poor, for example in the case of brain functions or the 
biology of ageing. In other cases, biomedical information and diagnostics are 
established, but there is no treatment, and/or clinicians will have to experiment 
with possible connections (work under clinical trial conditions).
Regulators may decide not to prioritise such clinical applications when cost 
and uncertainty are high, with low current cost-effectiveness ratio and in the 
absence of a societal decision to invest in the field. But research or testing 
should be continued in these areas, so that uncertainty and costs are reduced. 
Recommendation: Create a space for dialogue to discuss clinical applications 
with society, as it involves potentially large investments.
Strengthening the science base 
A major obstacle for the translation of research into 
clinical testing (let alone approval and clinical use) is 
the weakness of the molecular / biochemical scientific 
understanding of a disease in a controlled clinical 
setting. A better understanding of the pathological 
mechanisms is key. 
There is a huge potential for outcome-based treatments 
through app-based patient reporting (mHealth).
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3.
ADDRESSING  
THE DATA ISSUE
A roadmap for PM must include stakeholders addressing the ‘data issue’. 
The generation and use of data is one of the main drivers of change in the 
research and medical practice:
• PM requires a lot of data from individuals
• Handling genomic, health, medical, intimate and personal data poses 
various challenges that will have to be addressed by the stakeholders.
Specific actors for addressing the data issue include:
• Researchers
• Biobanks (of samples and data) which collect and act as a repository for 
genetic and other personal data.
• Industry that processes and analyses the data. This industry is currently 
operating without a clear legal framework. Here, regulation is needed 
to deal with industrial capacity to build, e.g. DNA printers or digital bio-
converters.
• Insurers who are active players in data collection and sharing, and thus 
enablers of precision medicine. 
On the ‘data’ agenda, any roadmap for PM must include:
• Work to determine which data are needed to improve the understanding of 
large-scale personal information and the link with specific health conditions.
• The level of precision or quality that is required.
Clarifying data privacy and confidentiality issues
DNA information is considered private and confidential. However, DNA 
information is difficult to protect, even when it is de-identified (anonymised), 
because it can sometimes be reconstructed from e.g. public information 
available on social media. DNA information is therefore in practice not as 
private as health data from medical records, which must be kept in strict 
privacy and can be protected. Furthermore, DNA information must be 
analysed. It acquires its value through the analysis process, during which it 
is assembled and interpreted together with other data. 
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The use of data should be non-discriminatory, even when the individual risk 
profile is known. Patients and civil society must be involved in the decisions 
that will be made about how data is used. They must determine what they 
want to protect and when confidentiality is required. The goal must be to 
develop ways to continue protecting what individuals care about in any 
circumstances. At this stage, this is a research question, but also a societal 
question which needs broad citizen involvement on at least some of its 
aspects.
Tasks to consider include: implementing data management with privacy 
and confidentiality in mind, defining data custodianship, controlling access, 
certifying institutions. 
Facilitating a societal dialogue  
and decisions about consent
Data is volunteered by or acquired from citizens and patients, who provide 
‘consent’. Citizens and the medical profession should work together to define 
the various types of consents and implications. Ideally, the development of 
trustworthy applications of genomics, in a way that is reliable, honest and 
accountable should encourage systems of unified general consent. Those 
systems must be informed and dynamic, implying that participating citizens 
have acquired knowledge about the research process, including potential 
future uses, and that they can maintain or withdraw their consent as new 
relevant information becomes available. There is, however, a distinction 
between consent for research and consent for industrial applications, and 
between consent to share data for private or public use. 
Therefore, any dialogue and decision must be very clear about what the 
donors (citizens) are consenting to, bearing in mind that beyond privacy, 
security and consent issues, what matters is trust.
Establishing a framework for data sharing
The trustworthiness that is anticipated to result from agreeing on a roadmap 
for precision medicine should allow for a sense of social responsibility in 
sharing data. Trustworthiness is established if the legitimate framework 
for data acquisition and sharing is clear about the purpose. This has not 
been established yet as shown by public reluctance to share health records 
(NHS England, 2013). It is critical to establish governance mechanisms and 
transparency for data sharing and use. 9 Under EU regulation, patients must 
be in control of their data (European Commission, DG JUSTICE, n.d.).
9 Examples of platforms for data and information sharing: www.matchmakerexchange.org, www.genematcher.org, www.midata.coop, 
www.healthbank.coop
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Like in any new development, it may be that certain things turn out to 
go wrong or not as expected. It would be presumptuous to neglect, for 
example, the possibility of misuse of data by actors with malicious intentions 
or for unauthorised purposes. To prevent negative consequences from such 
incidents, trusted authorities must develop their response plans in advance, 
in order to avoid a breach of trust. Plans may include such dispositions as 
the possibility for individuals to opt out of data sharing schemes, including 
removal of their own data, but also revisions of existing regulatory and liability 
regimes.
Developing biobanks and interoperability of data
Data standardisation and interoperability are necessary for data sharing. It 
is a technical problem but which nonetheless needs a political agreement to 
be resolved. Biobanks are organised at national and regional levels 10. Inter-
operability and traceability access will be important to clinicians, researchers 
and legislators.
Pursuing other advancements  
to deliver precision medicine
Scientific and technical advancements are transforming data collection and 
analysis, therapy delivery, and medicine overall. They include the use of 
connected medical sensors and devices (implantable or not) for monitoring 
and treatment, health wearables, or mobile health applications, which will 
help individuals monitor their own lifestyle and health. They also include 
advanced data analytics to feed artificial intelligence and deep learning, 
which can modify the medical practice through new types of algorithms that 
support decisions to be made by machines as much as by humans. Precision 
medicine develops in parallel with and benefits from these advancements. 
However, all medical treatments will still need to be assessed by established 
protocols of clinical trials.
Typology of applications based 
on the source of the data
Table 2 below proposes a typology of precision medicine applications (public, 
mixed and private), depending on the source of the data and the source of 
funding. We believe that this typology can help institutions structure their 
10 E.g. BBMRI-ERIC in Europe. See www.bbmri-eric.eu
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thinking about data acquisition and application, and help to bridge the gaps 
between scientific and biomedical research data on the one hand and clinical 
and patient lab data on the other hand. 11
Type Public Mixed Private
Data Source Public Public Public and private
Benefactor /  
Funder
Public /  
Government
Private /  
Government & Insurance
Private /  
Insurance and Private
Cost per Capita + ++ +++
Field of application Understanding Genetic 
Variations as basis for 
disease and poor health.
Fostering wellbeing and health 
through targeted prevention.
General knowledge of 
human genome & functions, 
health and wellbeing.
Re-tasking existing drugs 
for new diseases.
Selective use of existing 
drugs for existing diseases to  
(a) reduce side-effects and  
(b) improve efficacy.
New diagnostics and 
therapies targeted at 
individual patients, based on 
their genome, such as:
• cell therapies 
• gene therapies 
• immune activation
Table 2: Typology of applications.
11 Adapted from David Hanselman, Synthetic Genomics.
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4.
REFORMING REGULATION 
AND PAYMENT SYSTEMS
Advances in medicine result from an iterative process among scientists, 
industry, regulators, physicians, patients and other actors. Healthcare systems 
are adaptive. With precision medicine, they are expected to become even 
more adaptive and incorporate more learning by doing. Health care systems 
can improve by learning from experience through feedback processes, and 
adapt as new knowledge is made available about actual outcome (safety, 
efficacy) and economic benefits (cost-effectiveness). This might pose a 
challenge for PM, for instance if personalised treatments are applied to 
very small numbers of patients for which statistical proof is difficult. Since 
changes in regulatory systems take time, the discussion should start now, as 
it has begun at the European Medicines Agency. Important goals include re-
designing methods and metrics for assessing safety and efficacy, and paying 
for medical treatments according to their performance (effectiveness in use) 
(Breckenridge , Eichler, & Jarow, 2016). Precision medicine initiatives should 
consider deliberating and deciding about the following aspects.
Adaptive licensing
Processes are shifting from viewing decisions on licensing as a one-
time binary decision, to treating these decisions as an on-going process 
aiming at providing greater certainty about efficacy and safety as evidence 
accumulates. Adaptive licensing implies agreeing to review decisions. 
Regulators increasingly consider the design of legal structures with regulatory 
mechanisms that can adapt, so that those are more responsive to scientific 
knowledge and outcome. The principle is the following, as is already 
implemented in an EMA pilot project for new pharmaceuticals (European 
Medicines Agency, n.d.): Analyses are conducted during an original drug 
approval trial, adaptive trials collect and analyse patient response to the drug 
being tested, and biomarkers that cause certain patients to respond differently 
to the same treatment regiments are identified. Progressive adaptation is 
implemented during the drug or treatment lifecycle. Adaptive trials enable a 
learning feedback loop and require a different approach to post-marketing 
surveillance (see below). 
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Performance-based reimbursement
Some payers are shifting from viewing decisions on reimbursement as a 
one-time binary decision, to treating reimbursement decisions as an on-
going process aiming at providing greater certainty about value for money 
as evidence accumulates. Medical treatments are reimbursed on the basis 
of evidence of efficacy, safety and added value for money. Payers will 
increasingly decide what they want to pay, based on quality of outcome and 
cost-effectiveness 12. Their demand will increasingly focus on effectiveness 
in use (performance). Personalised healthcare must be able to provide the 
information on actual performance measured among small numbers of 
patients in adaptive trials. The development of metrics of success acceptable 
to payers and regulators is a major challenge. 
Regulate and pay for diagnostics and data analytics
Regulation and reimbursement usually focus on therapeutics. However, they 
increasingly need to account for the added value and cost of data collection 
and analysis, and diagnostics. For example, it may be that the molecular 
diagnostic is the best ‘value-added’ of some application of precision medicine, 
but most reimbursement schemes and regulations do not recognise this. 
Similarly, IT-based clinical decision-support systems and applications of 
evidence-based artificial intelligence must be compensated proportionate 
to their role in precision medicine. Revisions of reimbursement frameworks 
for data and diagnostics are needed.
Post-market surveillance
New tools for post-marketing surveillance and monitoring need to be 
established for both adaptive licensing and performance-based reimbursement 
to create the new data and feedback loops needed for the improvement of 
PM. This will be greatly enhanced by direct patient involvement using mobile 
applications and crowdsourcing.
In conclusion, with rising health care costs, health systems must take a more 
critical look at their existing financial/business model. Precision medicine may 
allow a shift from volume- to value-based payment methods that emphasise 
improved outcomes, with revised definitions of what is acceptable and 
affordable.
12 Principles and examples of performance-based or outcome-based contracts are provided in (OECD, 2013) and in chapter 5 of 
Howard & Huber, 2016.
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CONCLUDING 
REMARKS
Beyond the indispensible scientific advances in genomic science, we highlight 
seven elements that will influence the development of precision medicine:
1. Data generation is a major driver of change in medicine. All actors 
must fully integrate the implications of the fact that, in addition to being 
‘personalised’, precision medicine is also data-driven. 
2. Patients are expected to take more responsibility for their own health 
and disease, and insurance solutions might become more adaptive to 
patients’ behaviour.
3. Electronic medical records, made available by health care professionals 
and patients, should be used to track outcome, providing better information 
about effectiveness.
4. Artificial intelligence and deep learning could modify the medical 
practice, through new types of sensors, medical devices and algorithms 
that support decisions.
5. Business models for Big Data and complex intersecting datasets should 
be established, especially with the longitudinal nature of many PM data 
initiatives.
6.  As the pharmaceutical industry gets more information from adaptive 
clinical trials, it could deliver more competitive drugs, based on outcome. 
It could also be more willing to take on more of the risk in case a therapy 
does not perform as originally planned. 
7. Payers will have to work to determine new pricing mechanisms and 
schemes for large-scale biomedical data analysis and diagnostics. 
In their anticipation of the future, actors in the medical and health sectors 
are advised to consider these aspects.
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APPENDIX 1
ABOUT ROADMAPS  
FOR PRECISION MEDICINE
This paper suggests that national and international initiatives for precision medicine include 
a ‘roadmap’ of important considerations and milestones for achieving the vision of precision 
medicine. 
Several initiatives include the concept of roadmaps, which are:
• Multi-disciplinary – they consider both technical issues and societal issues.
• Multi-stakeholder – they acknowledge that the implementation of important improvements in 
the medical field necessitates more than a scientific judgement, because of implications in 
other fields.
From research and NGOs:
• Angela Brand & Jonathan Lal, European Best Practice Guidelines for Quality Assurance, 
Provision and Use of Genome-based Information and Technologies: the 2012 Declaration of 
Rome (Brand & Lal, 2012).
• European Science Foundation, Personalised Medicine for the European Citizen (European 
Science Fondation, 2012).
• European Alliance for Personalised Medicine (EAPM), Innovation and Patient Access to 
Personalised Medicine 13 (European Alliance for Personalised Medicine, 2013).
• Lada Leyens et al., Working towards personalization in medicine: main obstacles to reaching 
this vision from today’s perspective (Leyens, L., et al., 2014).
• Global Alliance for Genomics and Health (GA4GH), 2015-2016 Strategic Roadmap.14 
• PerMed, Shaping Europe’s Vision for Personalised Medicine; Strategic Research and Innovation 
Agenda (SIRA) (PerMed, 2015).
• ICPerMed Action Plan. A common Action Plan with actionable research and support activities 
in all areas related to personalised medicine (ICPerMed, 2017).
From governments and regulators:
• European Medicines Agency, Adaptive Pathways (European Medicines Agency, n.d.).
• US FDA, Precision Medicine Initiative (FDA, n.d.).
• Paving the Way for Personalized Medicine - FDA’s Role in a New Era of Medical Product 
Development (FDA, 2013).
• Roadmap for bringing personalized medicine to British Columbians (Personalized Medicine 
Initiative, 2015).
13 Report from Irish Presidency Conference March 2013 (European Alliance for Personalised Medicine) 
14 The GA4GH roadmap prioritises development and use of products, as well as the success of demonstration projects, leading to 
increased genomic data sharing and systemic change (Global Alliance for Genomics and Health, 2015/2016)
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Since 2005, the International Risk Governance Council (IRGC) has been developing 
recommendations for risk governance based on the knowledge that decision makers can collect 
about a risk issue (i.e. an issue in which there are risks involved, but often also opportunities or 
benefits) in order to (a) determine the type and extent of stakeholder involvement that is advisable, 
and (b) design decision processes and management strategies in which stakeholders’ objectives, 
constraints and needs will be taken into consideration. The table below is adapted from IRGC 
White Paper 1, Risk Governance: Towards an Integrative Approach, pages 16 and 53.23
23 IRGC. (2005). IRGC White Paper 1, Risk Governance: Towards an Integrative Approach. Retrieved from www.irgc.org/risk-governance/
irgc-risk-governanceframework
APPENDIX 2
IRGC BASIC RECOMMENDATIONS FOR 
RISK MANAGEMENT STRATEGIES
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Knowledge 
about the 
risk issue *
Simple Complex Uncertain Ambiguous
Cause and effects  
are known
Difficulty in identifying 
links between a 
multitude of potential 
causal agents and 
specific observed 
effects
Lack of clarity 
or quality of the 
scientific data. 
Absence of data 
(unknown)
Divergent  
or contested 
perspectives
Stakeholders 
who should be 
involved in the 
assessment 
and decision
Civil society  
(i.e. citizens)
Affected stakeholders 
(e.g. patients)
Affected stakeholders
(e.g. patients)
External scientists / 
researchers
External scientists / 
researchers
External scientists / 
researchers
Scientists, industry 
experts, regulators
Scientists, industry 
experts, regulators
Scientists, industry 
experts, regulators
Scientists, industry 
experts, regulators
Type of 
participation
Use existing routines 
to assess benefits and 
risks (and possible 
reduction measures)
Multi-disciplinary 
approach
Involve all affected 
stakeholders to 
collectively decide the 
best way forward
Societal debate about 
the risks, benefits and 
underlying implications
Type of 
management 
strategy
Regulation
Routine practices
Seek more 
information 
Make robust 
decisions, which 
will be acceptable in 
various contexts
Address uncertainty in 
the decision process
Be prudent, do not 
make decisions that 
are irreversible
Build resilience to fail-
ures, prepare to cope 
with negative outcome
Work to establish 
societal consensus, 
including about sharing 
benefits and risks
Work to resolve 
conflicts with dialogue 
and negotiation
Cost of  
the process
+ ++ +++ ++++
Potential return 
on investment
+ ++ +++ ++++
Application 
to precision 
medicine 
(tentative)
Horizon 1 Horizon 2 Horizon 3 Horizon 4
Collection 
of biomed- 
ical data: 
creating 
meaningful 
subpopu-
lations
Precision diagnostics: 
enabling precision 
treatments
Personalised 
prevention: when the 
biomedical profile is 
used for precision 
disease prevention 
and maintenance of 
wellbeing
New biomedical data-based 
therapies: when safety, efficacy  
and cost-effectiveness have not 
been demonstrated yet
Table 3: IRGC characterisation of knowledge and risk management strategies.
* For most risk issues, some elements of knowledge are ‘simple’, while others are ‘complex’, ‘uncertain’ or ‘ambiguous’. Managers 
try to address each level with appropriate methods. But all are interconnected
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APPENDIX 3
IRGC RECOMMENDATIONS FOR THE 
GOVERNANCE OF EMERGING RISKS
IRGC defines emerging risks as new risks or familiar risks 
that become apparent in new or unfamiliar conditions. 
In this context, risks are defined as the consequences 
of uncertainty on objectives, or what humans value. 
Emerging risks are characterised by uncertainty and 
change. Quite often, they are just described as ‘issues’, 
and it is not clear to managers and decision makers 
how potential benefits and threats interact. Often, 
stakeholders with different interests or viewpoints may 
contest the evidence, thus hesitating to engage in the 
venture that may lead to opportunities and/or risks.
Figure 2: IRGC guidelines for emerging risk governance 
(ERG)
             Make sense 
       of the present
   and explore 
the future
Review risk
 development
  and decisions
Implement strategy
Generate risk 
management 
options and 
formulate 
strategy  
Develop scenarios        
based on narratives   
and models
ERG
Conductor
Facilitate
Validate
Communicate
1
2
3
4
5
Choose relevant 
strategy option(s)
Option 1: Act on the factors that 
contribute to risk emergence
Option 2: Develop precautionary 
approaches
Option 3: Reduce vulnerability
Option 4: Modify the risk appetite 
in line with new risk
Option 5: Use risk governance 
instruments to manage familiar risk
Option 6: Do nothing
24 IRGC. (2015). Guidelines for Emerging Risk Governance. Lausanne: International Risk Governance Council (IRGC). Retrieved from 
irgc.org/risk-governance/emerging-risk/a-protocol-for-dealing-with-emerging-risks
IRGC’s guidelines for emerging risk governance, as 
illustrated in figure 2, include a process and recommended 
instruments and practices for evaluating and making 
decisions about these issues.24 
Applying the Guidelines to precision medicine:
• Steps 1 and 2 in the process would involve horizon scanning, foresight exercises and developing 
scenarios of possible futures with (or without) precision medicine, including best and worst 
case scenarios. Such exercises would include facilitated dialogues with stakeholders about 
how various scenarios could generate impacts, consequences, benefits, and risks to them. 
The output of Step 2 consists of informed explorative scenarios. 
• Step 3 would consider various development strategies and management options and help 
decision makers adopt a collaborative strategy for a coordinated development of precision 
medicine. One of the options (# 4) would involve increasing the willingness to take more risks 
in the short term, in return for long-term improved health benefits.
• After deciding on a strategy and implementing it (Step 4), Step 5 would create processes and 
a framework for post-surveillance and monitoring, thus allowing feedback to regulators and 
adapt as knowledge is acquired.
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